Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 499

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 499
---
) consists of interest income on TuHURA’s cash and cash equivalents, interest expense on borrowings under TuHURA’s convertible note agreements, and non-cashchanges in the fair value of TuHURA’s derivative liability associated with the make-whole premium on TuHURA’s convertible notes. Other income (expense) also included grant income from TuHURA’s NIH-fundedresearch grants completed in May 2023, employee retention tax credit for companies with employees affected during the COVID-19pandemic, and forgiveness of a paycheck protection program loan in April 2022. Preferred Series A Cash Dividend Preferred Series A cash dividend represents a cash dividend payable to Valent Technologies, LLC, the holder of TuHURA’s Series A Preferred Stock. Effective September 30, 2014, Kintara filed a Certificate of Designation of Series A Preferred Stock with the Secretary of State of Nevada, pursuant to which, Kintara designated and thereafter issued 278,530 shares of preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $1.00 per share (the “Series A Stated Value”) and are not convertible into shares of TuHURA Common Stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Series A Stated Value, payable quarterly in arrears. The dividend has been recorded as a direct increase in accumulated deficit. Warrant modification Warrant modification represents an extension of the exercise period of common stock purchase warrants issued in connection with Legacy TuHURA Series A Preferred Stock (the “Series A Warrants”) for an additional six months, with a new expiration date of February 12, 2025. The warrant modification has been recorded as a direct increase in accumulated deficit. Results of Operations Comparisons for the Years Ended December 31, 2024, and December 31, 2023

|                                                        |     | Year ended December 31, |        2024 |   |     |   |        2023 |   |     | Change |             |   |
|:-------------------------------------------------------|:----|:------------------------|------------:|:--|:----|:--|------------:|:--|:----|:-------|------------:|:--|
| Operating expenses:                                    |     |                         |             |   |     |   |             |   |     |        |             |   |
| Research and development                               |     | $